Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
56.08 USD | +18.34% | +14.73% | +422.65% |
16/04 | JonesTrading Starts Janux Therapeutics With Buy Rating, $70 Price Target | MT |
10/04 | Sector Update: Health Care Stocks Slipping Late Afternoon | MT |
Business Summary
Number of employees: 64
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Immunotherapies
100.0
%
| 9 | 100.0 % | 8 | 100.0 % | -6.14% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 9 | 100.0 % | 8 | 100.0 % | -6.14% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
David Campbell
CEO | Chief Executive Officer | 65 | 01/17/01 |
Tighe Reardon
DFI | Director of Finance/CFO | 48 | 01/17/01 |
Jenna Daly
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Tech/Sci/R&D Officer | - | 01/18/01 | |
Charles Winter
CTO | Chief Tech/Sci/R&D Officer | - | 01/21/01 |
Andy Meyer
IRC | Investor Relations Contact | 40 | 01/21/01 |
James Pennington
LAW | General Counsel | - | - |
Human Resources Officer | - | 23/22/23 | |
Byron Robinson
PRN | Corporate Officer/Principal | 59 | 01/22/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Vickie Capps
BRD | Director/Board Member | 62 | 18/21/18 |
Jay Lichter
CHM | Chairman | 62 | 01/17/01 |
Director/Board Member | 68 | 07/21/07 | |
David Campbell
CEO | Chief Executive Officer | 65 | 01/17/01 |
Alana McNulty
BRD | Director/Board Member | 61 | 07/21/07 |
Sheila Gujrathi
BRD | Director/Board Member | 53 | 18/21/18 |
Winston Kung
BRD | Director/Board Member | 48 | 22/22/22 |
Jake Simson
BRD | Director/Board Member | 38 | 01/21/01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 51,670,379 | 44,543,167 ( 86.21 %) | 10,319 ( 0.0200 %) | 86.21 % |
Company contact information
Janux Therapeutics, Inc.
10955 Vista Sorrento Parkway Suite 200
92130, San Diego
+
http://www.januxrx.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+422.65% | 2.9B | |
+1.77% | 42.86B | |
+45.21% | 41.36B | |
+12.24% | 42.74B | |
-8.83% | 27.68B | |
+7.44% | 25.15B | |
-23.01% | 18.63B | |
+30.56% | 12.37B | |
-1.82% | 11.92B | |
+8.35% | 11.21B |
- Stock Market
- Equities
- JANX Stock
- Company Janux Therapeutics, Inc.